Therapeutic interventions targeting OX40/OX40L interaction may help regulate T-cell responses and provide novel solutions to T-cell-mediated autoimmune diseases such as IgG4-RD. This evidence concerns the gene TNFSF4 and immunoglobulin G4-related sclerosing disease.